Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 1 of the 13 calendar months from Oct 2025 to Oct 2026: Jun 2026.
- Largest single sale: $366K (1,222 shares) of Alnylam Pharmaceuticals, Inc. on Jun 1, 2026. Filing
- Last sale before this period: Mar 24, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | Director | Feb 20, 2026 | Sep 17, 2026 |
| Alnylam Pharmaceuticals, Inc. (ALNY) | Director | Dec 22, 2015 | Jun 3, 2026 |
| Avery Dennison (AVY) | Former Director | Sep 30, 2003 | Apr 24, 2020 |
| Edwards Lifesciences (EW) | Former Director | May 17, 2004 | May 13, 2014 |
Also a director at
Alnylam Pharmaceuticals, Inc. (ALNY), Avery Dennison (AVY) (no filing in the last 18 months), Edwards Lifesciences (EW) (no filing in the last 18 months)
Recent filings
The last 4 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Sep 15, 2026, Tarsus Pharmaceuticals, Inc.: 201 shares vested (some held indirectly). 1 filing: 1
- Jun 1, 2026, Alnylam Pharmaceuticals, Inc.: sold 3,830 shares for $1.1M, under a disclosed plan; 3,830 shares acquired by exercising options. 1 filing: 1
- May 20, 2026, Alnylam Pharmaceuticals, Inc.: 671 shares granted. 1 filing: 1
- Apr 24, 2026, Tarsus Pharmaceuticals, Inc.: 1,383 shares vested. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.